About 1 in 4 of the more than 7 million Americans who require insulin to treat their diabetes skip doses or frequently use less than they need because they can’t afford the drug. Prices in the U.S. are far higher than in other industrialized nations, and efforts to bring them down have failed – until now.

As Jing Luo, a University of Pittsburgh Health Sciences researcher and doctor who specializes in diabetes, explains, there’s a promising new solution on the horizon.

A nonprofit generic drugmaker called Civica Rx recently announced that it will manufacture the most common versions of insulin and make sure that a month’s supply costs patients roughly $30 a month, starting in 2024. “I’m excited about this initiative because it promises to increase access to all people who require insulin in the U.S., regardless of insurance status or where they buy medications,” Luo writes.

Also today:

Emily Schwartz Greco

Philanthropy + Nonprofits Editor

Nonprofit drugmaker Civica Rx is taking aim at the high insulin prices harming people with diabetes

Jing Luo, University of Pittsburgh Health Sciences

About 1 in 4 Americans with diabetes who need insulin struggle to pay for this lifesaving drug.

Science + Technology

Arts + Culture

Health + Medicine

Ethics + Religion

Politics + Society

Economy + Business

Trending on site

Reader Comments 💬

More from The Conversation US